Catalent Stock - Long-term buyout by Novo Nordisk closes

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 14:10 UTC. Details in the imprint.

Catalent (US1488061029) is now part of Novo Holdings after the private investment arm of the Novo Nordisk Foundation completed its acquisition of the drug manufacturer in a multibillion-dollar deal. According to a Catalent IR release on 05/03/2024, the transaction has closed and the stock has been delisted from the New York Stock Exchange.

What the Novo deal changed

The acquisition agreement between Novo Holdings and Catalent was first announced on 02/05/2024, valuing Catalent at about $16.5 billion including debt, or $63.50 per share in cash for shareholders. The price represented a premium to Catalent’s prior unaffected trading level, reflecting the strategic value of its manufacturing footprint for fast-growing drugs such as GLP-1 therapies.

Following shareholder approval and regulatory clearances, Novo Holdings reported that the transaction closed in early May 2024, after which Catalent ceased to be an independent public company. All outstanding Catalent shares were converted into the right to receive the agreed cash consideration, and the stock was removed from the New York Stock Exchange listings.

Long-term strategic role within Novo Nordisk

Post-acquisition, Catalent is being reorganized as a key contract development and manufacturing platform within the Novo ecosystem, especially around injectable and biologic therapies. Novo Nordisk has been facing structurally high demand for its GLP-1 drugs for obesity and diabetes, and additional fill-and-finish capacity is central to its long-term supply strategy.

According to Novo Nordisk and Foundation communications, parts of Catalent’s network - in particular filling sites in Europe and the United States - are planned to support the production of semaglutide-based products over the coming years. This dovetails with Novo Nordisk’s multi-year capex plans to expand both internal and external manufacturing capacity for its flagship treatments.

How the company makes money

Catalent historically generated revenue by providing contract development and manufacturing services for pharmaceuticals, biologics and consumer health products. The company offered formulation development, clinical supply services and commercial-scale production, charging customers project-based development fees as well as ongoing manufacturing margins.

Its portfolio included oral solid dose technologies, sterile injectable manufacturing and cell and gene therapy capabilities. Customers ranged from large multinational drug makers to smaller biotech firms that preferred outsourcing complex production rather than building their own plants. Under Novo Holdings, Catalent continues to operate in this CDMO model but with a stronger anchor customer in Novo Nordisk.

Where the stock trades today

Catalent stock is no longer publicly traded after the completion of the cash acquisition and delisting from the New York Stock Exchange; former shareholders received cash consideration instead of ongoing listed shares.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.